Genflow Biosciences has received a research grant award of up to €3.375m from the regional government of Wallonia in southern Belgium.
Genflow, a UK-based biotechnology, is focused on the development of therapies to counteract the effects of ageing and diseases associated with advanced age.
It will use the grant to expedite its planned research and development activity, covering two years of costs of the pre-clinical research and development programme ‘AAV/SIRT6 Gene Therapy for the Treatment of Progeria’.
Dr Eric Leire, Founder and CEO of Genflow Biosciences, said: “We are incredibly delighted and honoured to receive this grant which will expedite the research and development programme Genflow conducts in the EU.
“I congratulate the team at Genflow for securing this supportive funding which validates the belief in our company and our long-term vision.
“This grant will enable Genflow to further expand its research which is designed to allow people to live longer, healthier lives.
“Access to non-dilutive public funding is highly prized and much sought-after, the support from SPW is a significant advantage to Genflow and will support our R&D efforts while helping us to maintain relatively low operating costs.”
